Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Raltegravir (MK-0518)
DRUG: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)